EGFR and neoplasm: A phenotypic change in slowly growing tumors subject to increased spacing between doses was observed in-vivo, with a reduction in the levels of phosphorylated EGFR and NF-κB, is associated with a MES-to-PN switch, as recently shown.22 This transition could explain the reduced aggressiveness of the tumors after long-cycle TMZ treatment, which does not seem to depend on changes in proliferation and/or survival of tumor cells.